New Zealand

Equivac 2 in 1

A purified adjuvanted vaccine containing the formalinised toxin of Clostridium tetani (tetanus toxoid) and a sterile, cell-free extract of Streptococcus equi (S. equi).

Expand All
  • Vaccination results in (1) an antitoxin response to protect horses against tetanus and (2) stimulation of the immune system to produce resistance to infection by S. equi.

  • 1mL single dose syringes in packs of 20.

    • HORSES: Inject 1mL dose of vaccine i/m. For primary immunisation, horses of 3 months of age or older should be given 3 doses of vaccine. It is recommended that the first dose given is Equivac 2 in 1, the second dose is Equivac 2 in 1 or Equivac S and the third dose is Equivac 2 in 1. The interval between doses should not be less than two weeks.
    • A booster dose of Equivac 2 in 1 or Equivac T should be given one year after the primary immunisation course to ensure long-lasting immunity against tetanus. It is advisable, particularly in valuable animals, to revaccinate against tetanus at intervals of approximately 5 years.
    • A single dose of Equivac 2 in 1 or Equivac T given to an unimmunised horse at the time of wounding or surgery may not prevent tetanus. For immediate short-term protection against tetanus, Equivac TAT (tetanus antitoxin) should be used. At the same time, active immunisation with Equivac 2 in 1 or Equivac T should commence.
    • For strangles, annual boosters are recommended. Increased protection against strangles may be obtained by administering booster doses more frequently and six-monthly re-vaccination should be considered in circumstances where the risk of strangles is known to be high. It is particularly important that booster doses be given prior to periods of greater risk of infection such as during the breeding season.
    • Pregnant mares may be vaccinated up to two weeks before foaling. Also see product literature.
    • Horses exhibiting symptoms of strangles should not be vaccinated. In an outbreak of strangles, horses should be segregated into 3 groups. Those affected by the disease should be treated and not vaccinated. Horses with no known contact should be vaccinated immediately. Horses known to have been in contact should be observed for 7 to 10 days and vaccinated only if they have normal temperatures and show no clinical signs.
    • Correct vaccination procedure is important.
    • Side effects, localised swelling may develop occasionally at the site of injection. On rare occasions, systemic signs may follow vaccination against strangles in horses sensitised to S. equi.
    • Withholding times: Nil.
    • Other information: Store at 2–8°C (refrigerate; do not freeze). Protect from light.
  • Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. EQUIVAC is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A6587. RVM; Available only under Veterinary Authorisation.

  • For technical enquiries regarding Equivac 2 in 1 please phone Zoetis Technical Services on:0800 650 277.